Melanoma immunotherapy in mice using genetically engineered pluripotent stem cells

Mohammad Haque, Jianyong Song, Kristin Fino, Praneet Sandhu, Youfei Wang, Bing Ni, Deyu Fang, Jianxun Song

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Adoptive cell transfer (ACT) of antigen (Ag)-specific CD8+ cytotoxic T lymphocytes (CTLs) is a highly promising treatment for a variety of diseases. Naive or central memory T-cell-derived effector CTLs are optimal populations for ACT-based immunotherapy because these cells have a high proliferative potential, are less prone to apoptosis than terminally differentiated cells, and have the higher ability to respond to homeostatic cytokines. However, such ACT with T-cell persistence is often not feasible due to difficulties in obtaining sufficient cells from patients. Here we present that in vitro differentiated HSCs of engineered PSCs can develop in vivo into tumor Ag-specific naive CTLs, which efficiently suppress melanoma growth. Mouse-induced PSCs (iPSCs) were retrovirally transduced with a construct encoding chicken ovalbumin (OVA)-specific T-cell receptors (TCRs) and survival-related proteins (i.e., BCL-xL and survivin). The gene-transduced iPSCs were cultured on the delta-like ligand 1-expressing OP9 (OP9-DL1) murine stromal cells in the presence of murine recombinant cytokines (rFlt3L and rIL-7) for a week. These iPSC-derived cells were then intravenously adoptively transferred into recipient mice, followed by intraperitoneal injection with an agonist a-Notch 2 antibody and cytokines (rFlt3L and rIL-7). Two weeks later, naive OVA-specific CD8+ T cells were observed in the mouse peripheral lymphatic system, which were responsive to OVA-specific stimulation. Moreover, the mice were resistant to the challenge of B16-OVA melanoma induction. These results indicate that genetically modified stem cells may be used for ACT-based immunotherapy or serve as potential vaccines.

Original languageEnglish (US)
Article number17
Pages (from-to)811-827
Number of pages17
JournalCell Transplantation
Volume25
Issue number5
DOIs
StatePublished - Jan 1 2016

Fingerprint

Pluripotent Stem Cells
T-cells
Adoptive Transfer
Ovalbumin
Stem cells
Immunotherapy
Melanoma
Cytotoxic T-Lymphocytes
Cytokines
T-Lymphocytes
CD8 Antigens
Lymphatic System
Experimental Melanomas
Antigens
Neoplasm Antigens
Stromal Cells
T-Cell Antigen Receptor
Intraperitoneal Injections
Chickens
Cell Survival

All Science Journal Classification (ASJC) codes

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Cite this

Haque, M., Song, J., Fino, K., Sandhu, P., Wang, Y., Ni, B., ... Song, J. (2016). Melanoma immunotherapy in mice using genetically engineered pluripotent stem cells. Cell Transplantation, 25(5), 811-827. [17]. https://doi.org/10.3727/096368916X690467
Haque, Mohammad ; Song, Jianyong ; Fino, Kristin ; Sandhu, Praneet ; Wang, Youfei ; Ni, Bing ; Fang, Deyu ; Song, Jianxun. / Melanoma immunotherapy in mice using genetically engineered pluripotent stem cells. In: Cell Transplantation. 2016 ; Vol. 25, No. 5. pp. 811-827.
@article{0f9fb7ea3d07456caad1bb1f53b35ee3,
title = "Melanoma immunotherapy in mice using genetically engineered pluripotent stem cells",
abstract = "Adoptive cell transfer (ACT) of antigen (Ag)-specific CD8+ cytotoxic T lymphocytes (CTLs) is a highly promising treatment for a variety of diseases. Naive or central memory T-cell-derived effector CTLs are optimal populations for ACT-based immunotherapy because these cells have a high proliferative potential, are less prone to apoptosis than terminally differentiated cells, and have the higher ability to respond to homeostatic cytokines. However, such ACT with T-cell persistence is often not feasible due to difficulties in obtaining sufficient cells from patients. Here we present that in vitro differentiated HSCs of engineered PSCs can develop in vivo into tumor Ag-specific naive CTLs, which efficiently suppress melanoma growth. Mouse-induced PSCs (iPSCs) were retrovirally transduced with a construct encoding chicken ovalbumin (OVA)-specific T-cell receptors (TCRs) and survival-related proteins (i.e., BCL-xL and survivin). The gene-transduced iPSCs were cultured on the delta-like ligand 1-expressing OP9 (OP9-DL1) murine stromal cells in the presence of murine recombinant cytokines (rFlt3L and rIL-7) for a week. These iPSC-derived cells were then intravenously adoptively transferred into recipient mice, followed by intraperitoneal injection with an agonist a-Notch 2 antibody and cytokines (rFlt3L and rIL-7). Two weeks later, naive OVA-specific CD8+ T cells were observed in the mouse peripheral lymphatic system, which were responsive to OVA-specific stimulation. Moreover, the mice were resistant to the challenge of B16-OVA melanoma induction. These results indicate that genetically modified stem cells may be used for ACT-based immunotherapy or serve as potential vaccines.",
author = "Mohammad Haque and Jianyong Song and Kristin Fino and Praneet Sandhu and Youfei Wang and Bing Ni and Deyu Fang and Jianxun Song",
year = "2016",
month = "1",
day = "1",
doi = "10.3727/096368916X690467",
language = "English (US)",
volume = "25",
pages = "811--827",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "5",

}

Haque, M, Song, J, Fino, K, Sandhu, P, Wang, Y, Ni, B, Fang, D & Song, J 2016, 'Melanoma immunotherapy in mice using genetically engineered pluripotent stem cells', Cell Transplantation, vol. 25, no. 5, 17, pp. 811-827. https://doi.org/10.3727/096368916X690467

Melanoma immunotherapy in mice using genetically engineered pluripotent stem cells. / Haque, Mohammad; Song, Jianyong; Fino, Kristin; Sandhu, Praneet; Wang, Youfei; Ni, Bing; Fang, Deyu; Song, Jianxun.

In: Cell Transplantation, Vol. 25, No. 5, 17, 01.01.2016, p. 811-827.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Melanoma immunotherapy in mice using genetically engineered pluripotent stem cells

AU - Haque, Mohammad

AU - Song, Jianyong

AU - Fino, Kristin

AU - Sandhu, Praneet

AU - Wang, Youfei

AU - Ni, Bing

AU - Fang, Deyu

AU - Song, Jianxun

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Adoptive cell transfer (ACT) of antigen (Ag)-specific CD8+ cytotoxic T lymphocytes (CTLs) is a highly promising treatment for a variety of diseases. Naive or central memory T-cell-derived effector CTLs are optimal populations for ACT-based immunotherapy because these cells have a high proliferative potential, are less prone to apoptosis than terminally differentiated cells, and have the higher ability to respond to homeostatic cytokines. However, such ACT with T-cell persistence is often not feasible due to difficulties in obtaining sufficient cells from patients. Here we present that in vitro differentiated HSCs of engineered PSCs can develop in vivo into tumor Ag-specific naive CTLs, which efficiently suppress melanoma growth. Mouse-induced PSCs (iPSCs) were retrovirally transduced with a construct encoding chicken ovalbumin (OVA)-specific T-cell receptors (TCRs) and survival-related proteins (i.e., BCL-xL and survivin). The gene-transduced iPSCs were cultured on the delta-like ligand 1-expressing OP9 (OP9-DL1) murine stromal cells in the presence of murine recombinant cytokines (rFlt3L and rIL-7) for a week. These iPSC-derived cells were then intravenously adoptively transferred into recipient mice, followed by intraperitoneal injection with an agonist a-Notch 2 antibody and cytokines (rFlt3L and rIL-7). Two weeks later, naive OVA-specific CD8+ T cells were observed in the mouse peripheral lymphatic system, which were responsive to OVA-specific stimulation. Moreover, the mice were resistant to the challenge of B16-OVA melanoma induction. These results indicate that genetically modified stem cells may be used for ACT-based immunotherapy or serve as potential vaccines.

AB - Adoptive cell transfer (ACT) of antigen (Ag)-specific CD8+ cytotoxic T lymphocytes (CTLs) is a highly promising treatment for a variety of diseases. Naive or central memory T-cell-derived effector CTLs are optimal populations for ACT-based immunotherapy because these cells have a high proliferative potential, are less prone to apoptosis than terminally differentiated cells, and have the higher ability to respond to homeostatic cytokines. However, such ACT with T-cell persistence is often not feasible due to difficulties in obtaining sufficient cells from patients. Here we present that in vitro differentiated HSCs of engineered PSCs can develop in vivo into tumor Ag-specific naive CTLs, which efficiently suppress melanoma growth. Mouse-induced PSCs (iPSCs) were retrovirally transduced with a construct encoding chicken ovalbumin (OVA)-specific T-cell receptors (TCRs) and survival-related proteins (i.e., BCL-xL and survivin). The gene-transduced iPSCs were cultured on the delta-like ligand 1-expressing OP9 (OP9-DL1) murine stromal cells in the presence of murine recombinant cytokines (rFlt3L and rIL-7) for a week. These iPSC-derived cells were then intravenously adoptively transferred into recipient mice, followed by intraperitoneal injection with an agonist a-Notch 2 antibody and cytokines (rFlt3L and rIL-7). Two weeks later, naive OVA-specific CD8+ T cells were observed in the mouse peripheral lymphatic system, which were responsive to OVA-specific stimulation. Moreover, the mice were resistant to the challenge of B16-OVA melanoma induction. These results indicate that genetically modified stem cells may be used for ACT-based immunotherapy or serve as potential vaccines.

UR - http://www.scopus.com/inward/record.url?scp=84964293364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964293364&partnerID=8YFLogxK

U2 - 10.3727/096368916X690467

DO - 10.3727/096368916X690467

M3 - Article

C2 - 26777320

AN - SCOPUS:84964293364

VL - 25

SP - 811

EP - 827

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 5

M1 - 17

ER -